Safe, sensible, sagacious: responsible scanning of pacemaker patients
We were quite concerned reading the recent editorial by Dr Edward T. Martin.
1 Some statements are erroneous and some recommendations made are potentially dangerous if followed by the readers of the European Heart Journal.
As earlier, 2 Martin overstates the problem of denying device patients MRI. The cited study by Sakakibara and Mitsui 3 does not report that '17% of patients with pacemakers were denied MRI in the previous year' as stated by Martin We were puzzled that even after recently responding to a 'Letter to the Editor' in the Journal of the American College of Cardiology reporting, among other issues, the unreliability of ECG monitoring during MRI, 11 Martin continues to state that 'pulse oximetry monitoring is not necessary' during MRI of a device patient. 1 Given the seriousness of the potential complications (death) and the unreliability of ECG monitoring during MRI, 7,10,11 we remain perplexed why such a simple safety measure is not recommended as has been by others. Limitations of the study evaluating fibrinolytic therapy and in-hospital PCI for ST-elevation myocardial infarction
We read with interest the article by McClelland et al. 1 entitled 'Percutaneous coronary intervention and 1-year survival in patients treated with fibrinolytic therapy for acute ST-elevation myocardial infarction'. We would like to congratulate the authors on their study, but would like to highlight a few limitations that may have influenced the study findings.
The 154 patients treated by in-hospital percutaneous coronary intervention (PCI) in the study received fibrinolytic therapy more quickly compared with those who had no in-hospital PCI; the median pain-toneedle time was significantly shorter in those who later underwent PCI than those who did not. This would have clearly influenced the outcome, as those in the PCI group were likely to have salvaged more myocardium. The median time difference between the two groups was 1.4 h and when we consider that 'minutes means muscle', 1.4 h implies a lot of muscle. A recent systematic review article by Gersh et al. 2 suggests that patients presenting within the first 2-3 h of symptom onset benefit most in terms of myocardial salvage by undergoing prompt reperfusion therapy. This being the case, those in the PCI group of the study by McClelland et al. 1 would have benefited more, not necessarily because of in-hospital PCI but rather because of more prompt reperfusion with fibrinolytic therapy with a resultant bias favouring the PCI group.
A second factor that may have favoured the PCI group was also eluded in the accompanying editorial by Danchin. 3 The majority of patients in the PCI group went to the cardiac catheter lab .24 h after admission (59%). This means that patients in the PCI group had survived at least up till the point of being taken to the cath lab. Those who died very early on in their admission may not have been taken to the cath lab because of this delay and would have been counted within the non-PCI group, resulting in bias favouring the PCI group.
McClelland et al. 1 do not provide any data on the usage of platelet glycoprotein IIb/IIIa inhibitors in their study. The combination of fibrinolytics with these agents has raised concerns about bleeding risks of subsequent PCI, but there is a paucity of data. 2 However, clarification concerning the use of such agents would provide the reader with useful information.
We once again congratulate the authors on their study of this important topic, but highlight some limitations that may have affected its findings.
